An international consensus now defines MAFLD through steatosis and diabetes/obesity or two metabolic abnormalities
Regulators are increasingly scrutinizing the fast-growing peptide market
Semaglutide and tirzepatide allow for albumin binding and resistance to DPP4 degradation, creating a significantly longer half-life (5 days for tirzepatide and 7 days for semaglutide) and thus a greater effect on receptors and downstream pathways in the central nervous, cardiovascular, digestive, and musculoskeletal systems as described below [37, 38]
Results vary, but some people report milder side effects with tirzepatide
Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT randomized controlled trial
Furthermore, the study cohort included individuals who either switched to or added on treatment with other glucose-lowering drugs